Comparative Pharmacology
Head-to-head clinical analysis: CAPITAL AND CODEINE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPITAL AND CODEINE versus QDOLO.
CAPITAL AND CODEINE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Codeine is a prodrug converted to morphine, which acts as a mu-opioid receptor agonist, producing analgesia and CNS depression. Acetaminophen inhibits cyclooxygenase (COX) enzymes centrally, reducing prostaglandin synthesis and pain perception.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Acetaminophen 300 mg plus codeine phosphate 30 mg orally every 4 hours as needed for pain; maximum acetaminophen 3000 mg/day, codeine 180 mg/day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Codeine: 2.5-3 hours; Codeine-6-glucuronide: 2.5-3 hours; Morphine: 1.5-4.5 hours. Clinical context: In poor CYP2D6 metabolizers, half-life may be prolonged due to reduced clearance.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal: 90% (codeine and metabolites, primarily as codeine-6-glucuronide and norcodeine), Biliary/Fecal: <10%
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist